

Special Issue

CD24 - a Novel Target for Cancer Therapy and a Biomarker for Cancer Prediction

Message from the Guest Editors

CD24 is a small, glycoposphatidylinositol-anchored cell surface receptor with a diverse array of functions; when adaptive immunity, inflammation, autoimmunity and cancer are just some of them. In recent years, *CD24* gene has raised considerable interest in tumor biology and poor treatment outcome. It has been identified as a new prognostic factor, stem cell marker in the human neoplasm and a biomarker for early detection of cancer. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth, metastasis and chemo-resistant. The biology of CD24 is intriguing but still not completely understood. With this special issue on CD24, we wish to stimulate increased awareness of this tiny *gene* and summarize the major findings associated with CD24 to stimulate new ideas for further research that may reveal the underlying link among the diverse processes mediated by CD24. Therefore we are soliciting for new original and exciting manuscripts that will shed light on its crucial role and potential applications in pathological and healthy situations.

Guest Editors

Prof. Dr. Nadir Arber

Health Promotion Center and Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Dr. Shiran Shapira

The Integrated Cancer Prevention Center, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Deadline for manuscript submissions

closed (25 June 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/45252

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).